Longeveron

Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results
Sponsored
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Sponsored
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Sponsored
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Sponsored
Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™
Sponsored
Nearly A Third Of Japan's 36 Million Seniors Are At Risk Of Aging Frailty – Could Lomecel-BTM, Longeveron's (NASDAQ: LGVN) Cell Therapy Help?
Sponsored
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
Sponsored

Longeveron Recent News

Longeveron – This Biotech Company Is Using The Body's Own Cells To Fight Age-Related Diseases
Wa'el Hashad, CEO of Longeveron (NASDAQ: LGVN), was recently interviewed by Benzinga.
Sponsored
Longeveron Announces Key Additions To Its Leadership Team And Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases.
Sponsored
Longeveron – Regenerative Medicine Developer Announces 100% Long Term Survival Rate For Children With HLHS
Hypoplastic left heart syndrome, or HLHS, has a historical mortality rate of 20% within five years of diagnosis. The disease affecting children may have a new therapy in Longeveron’s (NASDAQ: LGVN) Lomecel-B.
Sponsored
HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron's Lomecel-B Improve Outcomes?
Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome.
Sponsored
Longeveron Doses First Patient In Phase 2 Clinical Trial Of Lomecel-B™ In Japan For Aging-Related Frailty
Longeveron Inc. (NASDAQ: LGVN) announced that the first patient has been treated with Lomecel-BTM in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan. The trial aims to enroll 45 patients and its primary objective is to evaluate safety. 
Sponsored
LGVN: Updating Model Following 2Q Results
We are maintaining our Buy rating and $20 (peak sales-based) price target on Longeveron (NASDAQ: LGVN). The company reported 2Q results on Friday, with 2Q operating expenses of $4.4M versus our $5.4M estimate. 2Q revenue of $0.5M exceeded our $0.2M estimate, on higher clinical trial revenue than we had modeled.
Sponsored
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028.
Sponsored
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)
Sponsored
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. 
Sponsored
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.
Sponsored
Who Is Donald Soffer And What Is His Legacy?
Miami-based Donald Soffer embodies the entrepreneurial spirit and vision of his ancestors who escaped Europe in search of opportunity in America. Here’s what you need to know about the 89-year-old billionaire businessman and his family.
Longeveron Partners With US Department Of Veterans Affairs For Its Phase 2 Alzheimer's Trial
Photo by Caleb Fisher on Unsplash
Sponsored
Leading Medical Journal Publishes Study Of Longeveron's Phase 1 Trial Results For Alzheimer's Disease
Image sourced from Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Sponsored
Healthspan, Not Lifespan Should Be the Focus of Anti-Aging Research, Says Longeveron
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Sponsored
Longeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress
Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer’s Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1) Lomecel-B for HLSH Granted Rare Pediatric Disease and Orphan Drug Designation by the US FDA 
Sponsored
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
 
Sponsored
Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment
  The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. --Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. 
Sponsored
Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Photo by Anna Shvets from Pexels
Sponsored
Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. - Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease -
Sponsored
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. - Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease -
Sponsored

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved